Health
Eli Lilly chief reports growing uptake for obesity pill Foundayo
One-third of new GLP-1 pill patients take Foundayo, Eli Lilly's chief told CNBC as Texas plant construction began.
The short version
- Eli Lilly CEO Dave Ricks stated that one-third of new GLP-1 pill patients are now starting on Foundayo, with market share rising week over week.[CNBC]
- The drugmaker broke ground on a $6.5 billion production facility in Houston, Texas, designed to manufacture Foundayo and other small-molecule active ingredients.[CNBC]
- Eli Lilly plans to launch Foundayo in additional international markets in coming months, though the Houston facility is not scheduled to become operational until 2030.[CNBC]
Key facts
- Eli Lilly broke ground on a $6.5 billion production facility across roughly 240 acres in Houston, Texas.[CNBC]
- CEO Dave Ricks stated that one-third of new GLP-1 pill patients are starting on Lilly's obesity drug Foundayo.[CNBC]
- The new Houston facility is expected to be operational by 2030.[CNBC]
- The plant will manufacture active ingredients for Foundayo as well as medicines across oncology, immunology, neuroscience, and cardiometabolic health.[CNBC]
What remains uncertain
- The operational timeline extends to 2030, leaving the facility's eventual capacity and construction timetable subject to multi-year development risks.[CNBC]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.